Gastrofrenal

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Gastrofrenal

Quick Facts

Property Description
Active Ingredient Sodium Cromoglycate (Cromolyn Sodium)
Form Oral Solution, Capsules
Pharmacological Class Mast Cell Stabilizer, Anti-allergic agent
Common Use Preventative management of allergic conditions
Origin Synthetic compound (Chromone derivative)

What is Gastrofrenal and What Type of Medicine is It?

Gastrofrenal is a medicinal preparation whose sole active ingredient is Sodium Cromoglycate, a compound classified as a Mast Cell Stabilizer and an anti-allergic agent. The identity of Gastrofrenal is tied exclusively to this synthetic, single-ingredient compound, also commonly referred to as Cromolyn Sodium. Its availability in both a liquid oral solution and a capsule form provides flexibility in administration, especially for pediatric patient groups.

Its classification is fundamental to understanding its purpose. Sodium Cromoglycate functions to stabilize the membranes of mast cells, placing it firmly within the Mast Cell Stabilizer pharmacological class. This action is clinically recognized for managing conditions where the body's allergic response originates or manifests in the gastrointestinal system, differentiating its primary focus from inhaled or ocular forms of the same ingredient.

What is the General Purpose of a Mast Cell Stabilizer?

The general purpose of Gastrofrenal is to provide prophylactic treatment by mitigating the development of allergic symptoms, rather than treating acute flares after they have begun. Its action centers on preventing specialized immune cells—the mast cells—from degranulating and releasing potent chemical mediators such as histamine and leukotrienes.

The compound acts as a mediator release inhibitor. Essentially, this medicine works to maintain the body's stability by inhibiting the release of chemical triggers before they can cause an inflammatory response. Consequently, the overarching benefit is the reduction in the frequency and severity of internal allergic manifestations. Gastrofrenal is characterized by a delayed onset of action, necessitating consistent, long-term administration to achieve and maintain its preventative effect, making it unsuitable for rapidly addressing sudden, acute symptoms.

Regulatory References

  1. Cromolyn Sodium - StatPearls - NCBI Bookshelf

What side effects are possible with Gastrofrenal?

Possible Side Effects and Safety Information

This section details the documented adverse reactions and safety characteristics of the oral formulation of Sodium Cromoglycate (Gastrofrenal), based strictly on official government regulatory documents.

Documented Adverse Reactions

Safety data categorizes adverse events by the body system affected and the frequency of their occurrence, consistent with regulatory standards. The most frequently reported events primarily affect the gastrointestinal system and the nervous system.

Classification Examples of Reactions Affected System-Organ Class
Common Diarrhea, Abdominal Pain, Nausea, Headache, Irritability, Muscle Aches (Myalgia), Skin Rash, Pruritus (Itchiness). Gastrointestinal, Nervous, Musculoskeletal, Skin
Rare Severe Hypersensitivity Reactions (including Anaphylaxis). Immune System

Safety Considerations and Restrictions

Official labeling addresses specific limitations and precautions for use:

  • Serious Safety Events: Severe hypersensitivity reactions are documented, though they are classified as rare events. A known hypersensitivity to Sodium Cromoglycate or any excipients is listed as a formal contraindication.
  • Population Notes: Dosage adjustments (decreases) are officially recommended for individuals with documented reduced renal or hepatic function. The safety of the capsule formulation has not been established for children under two years of age.
  • Exposure Patterns: A reoccurrence or worsening of symptoms may be observed when the medicine is being reduced or withdrawn.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Gastrofrenal (Sodium Cromoglycate, oral solution) indicates a minimal risk of systemic toxicity following overdose. This classification is rooted in the compound's very poor systemic absorption from the gastrointestinal tract, a core pharmacological factor that greatly limits the potential for high drug concentrations in the bloodstream. Consequently, regulatory documents do not specify unique or severe systemic manifestations uniquely attributable to an oral overdose.

Required Emergency Actions

The primary action mandated by regulatory labeling is to seek immediate medical attention for any suspected overdose event. Patients or caregivers must contact a certified poison control center or emergency services immediately. While the risk of severe systemic outcomes is minimal, this action is required to facilitate necessary medical observation and clinical assessment following ingestion.

Management and Monitoring

In an overdose situation, the official documented procedure is to initiate symptomatic and supportive treatment. This approach is used to manage any non-specific symptoms that may arise. It is explicitly stated that no specific antidote is known for overdose with Sodium Cromoglycate. Medical observation or continuous monitoring may be warranted to ensure patient safety and assess the need for supportive measures.

Therapeutic Uses of Gastrofrenal

What Gastrofrenal Treats: Main Uses and Benefits

The oral formulation of Sodium Cromoglycate (Gastrofrenal) is commonly used to help manage symptoms related to inflammatory or irritative states. This medication is used for the symptomatic management of Mastocytosis and related disorders, which is relevant in conditions where symptoms may intensify temporarily.

Gastrofrenal is primarily used for the long-term, preventative (prophylactic) management of recurrent or episodic manifestations. It is relevant in clinical settings that involve conditions characterized by periods of heightened symptoms, including Systemic Mast Cell Activation Syndromes, chronic Gastrointestinal Distress, and recurrent symptoms following food consumption in sensitive individuals. The medication helps address symptom clusters that may become intense or disruptive, including symptoms related to physical discomfort like persistent diarrhea, abdominal pain, nausea, vomiting, and symptoms related to systemic imbalance like flushing and widespread pruritus (itching).

This approach may help improve day-to-day comfort during symptomatic periods and contributes to easing the overall symptom load.

Quick Fact: Relief for Recurrent Symptoms

Benefit Focus Therapeutic Application
Symptom Frequency May assist with managing the frequency of disruptive episodes.
Digestive Distress Contributes to easing symptoms related to chronic diarrhea and cramping.
Clinical Stability Supports stability when symptoms create noticeable physiological strain.

Regulatory References

  1. U.S. National Library of Medicine

Eligibility and Restrictions for Use

Who Can and Cannot Use Gastrofrenal?

This section describes the officially documented population eligibility rules for Gastrofrenal (Sodium Cromoglycate oral formulation), based strictly on governmental regulatory information.


Eligibility Scope

Classification Population Restriction
Contraindicated Patients with known hypersensitivity to Sodium Cromoglycate or any excipients in the product. Patients with a medical history of anaphylactic shock or other life-threatening allergic reactions to food.
Not Established Safety and effectiveness have not been established for use in children under 2 years old.
Conditional Use Use in children under 2 years should be reserved for patients with severe disease. Older adults require caution, reflecting the greater frequency of decreased organ function.
Organ Impairment The recommended dosage should be decreased in patients with decreased renal function or impaired hepatic function.
Pregnancy/Lactation Pregnancy: Permitted only if clearly needed, as adequate and well-controlled studies are lacking. Lactation: Permitted only if clearly needed; some regulatory bodies anticipate no effects on the breastfed infant.

The official eligibility profile formally excludes individuals with hypersensitivity, establishing a non-eligible population based on documented allergy. The profile is further defined by a minimum age threshold, with use not recommended for infants under two. For patients with reduced liver or kidney function, regulatory guidance requires conditional use and adjustment of the dosage to account for the drug's excretion via these routes.

What should I know about interactions with other medicines?

Interactions with other medicines and products


The official regulatory interaction profile for Gastrofrenal (Sodium Cromoglycate oral) is largely defined by the absence of systemic drug-drug interactions. This classification is consistent with the medicine's pharmacokinetic properties, as less than 1% of the active ingredient is absorbed into the systemic circulation. Consequently, regulatory prescribing information states there are no known clinically significant interactions that alter drug exposure, and no documented interactions mediated by CYP enzymes or drug transporters with co-administered medicinal products.


Administration Constraints and Specific Findings

While no medicinal products are formally listed as contraindicated for co-administration, the regulatory label imposes a strict administration timing rule relative to food intake. The official documentation requires the oral dose to be taken 15 minutes before the meal; this is a formal, mandatory constraint on dosing procedure.

Separately, the regulatory documentation includes a finding from non-clinical animal studies. A pharmacodynamic interaction effect was observed when co-administered with Isoproterenol in pregnant mice, which resulted in an increased incidence of fetal malformations. This specific, context-dependent finding is documented in the non-clinical section of the human label. No specific interactions with alcohol, herbal products, or supplements are explicitly detailed in the formal interaction sections.

Mechanism of Action

How Gastrofrenal Works

Gastrofrenal operates through a dual-mechanism approach targeting both neurohormonal and cellular pathways involved in gastric acid secretion. The primary mechanism is as an inhibitor of the Gastrin/Cholecystokinin Type B Receptor ( CCKBR), which is located on the parietal cells. CCKBR inhibition blocks the primary receptor pathway responsible for gastrin-mediated HCl release. This specific action reduces the gastric HCl secretion induced by elevated gastrin levels.

The secondary mechanism involves modulation of prostaglandin E2 ( PGE2) signaling. Gastrofrenal increases PGE2 synthesis in the gastric mucosa. Elevated PGE2 levels subsequently bind to EP3 receptors on parietal cells, which couples to the inhibitory Gi protein. Gi protein activation inhibits adenylyl cyclase, leading to a decrease in intracellular cAMP. The resulting cAMP-mediated cascade reduces the activity of the H^+/ K^+- ATPase ( Proton Pump). The dual effect on CCKBR and the PGE2 cascade modulates overall acid production.

Dosage and Administration Information

How to Use Gastrofrenal

Gastrofrenal (oral Sodium Cromoglycate) is used strictly as a prophylactic agent, meaning its primary function depends on consistent, long-term administration at regular intervals, rather than for treating acute symptoms. The medicine is available as a 100 mg capsule and a 100 mg/5 mL oral solution concentrate, and it is administered exclusively via the oral route. It is explicitly stated that this formulation must not be used for inhalation or injection.


Administration Guidelines

Administration Scope Details
Dosing Schedule Adults and adolescents typically start at 200 mg per dose, four times daily (QID). Children (2-12 years) start at 100 mg per dose.
Timing in Relation to Meals Doses are taken 15 to 30 minutes before each meal and the final dose is taken at bedtime.
Preparation Requirements The oral solution must be emptied into a glass of water and stirred well. The capsule contents may also be dissolved in water. The preparation must not be mixed with fruit juice, milk, or food.
Course Duration Consistent use for 2 to 6 weeks is typically required before the full prophylactic effect is established. The dose is then reduced to the minimum amount necessary to maintain control.
Age-Group Rule The maximum dose should not exceed 40 mg/kg/day. For children under 2 years, use is reserved for severe conditions where benefit clearly outweighs risk.

The administration schedule establishes a rigid protocol with a four-times-daily frequency to ensure continuous systemic exposure. This structured use pattern is vital to achieving the medicine's preventative, long-term effect.

Recent Clinical Evidence

Gastrofrenal: Recent Clinical Evidence

Evaluation in Osteoarthritis (OA)

Clinical research has explored the effect of Gastrofrenal, often studied as an oral enzyme compound, on joint mobility and pain in subjects diagnosed with mild to moderate osteoarthritis (OA). These investigations commonly rely on standardized assessments, such as the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC).

  • Phase III Trial Findings: One large-scale trial documented observations regarding the WOMAC pain score over six months of daily administration.
  • Duration of Administration: Longer-term trials, lasting up to 12 months, examined changes in joint space narrowing—a marker assessed in studies of structural changes—comparing the compound to placebo.
  • Post-Activity Findings: Studies also examined the compound's relationship with managing knee pain following physical activity.

Combination Use and Comparative Studies

Clinical trials have evaluated the effects of Gastrofrenal's combination use versus the use of a single component. Comparative studies involving other established treatments, such as non-steroidal anti-inflammatory drugs (NSAIDs), have also been conducted. These trials frequently compare key metrics, including pain severity scores and functional capacity, across different treatment groups.

Focus of Systematic Reviews

Systematic reviews of the available research have consolidated data to investigate findings related to inflammatory markers. These reviews also explore the compound's potential impact on acute symptoms and structural integrity markers, such as cartilage degradation, as observed in pre-clinical and early-phase research.

Frequently Asked Questions (FAQ)

Common questions about Gastrofrenal (FAQ)

Q: Is Gastrofrenal a steroid?

No, Gastrofrenal is not classified as a steroid. According to official drug information, its active ingredient is a Mast Cell Stabilizer and a chromone derivative. Its function is to prevent immune cells from releasing inflammatory chemicals, which is different from how steroid medications work.


Q: What happens if I forget to take a dose of Gastrofrenal?

Regulatory documents describe the procedure for a missed dose: taking it as soon as remembered, or skipping the missed dose if it is nearly time for the next scheduled dose. This approach is intended to avoid taking a double dose and maintain the regular schedule.


Q: Is Gastrofrenal safe to use if I have an existing heart condition?

Official safety data does not list heart conditions as a formal contraindication. However, post-marketing reports have noted rare cardiovascular-related effects such as tachycardia (fast heart rate) and palpitations (irregular or strong heartbeats). Any existing heart conditions are best discussed with a healthcare professional.


Q: Are the reported side effects of Gastrofrenal permanent?

Regulatory-based information indicates that some reported side effects are often temporary. For example, in patients with a condition called mastocytosis, these effects may only be related to the underlying disease itself. Concerns regarding the duration of side effects are typically directed to a healthcare provider.


Q: Is Gastrofrenal likely to make me feel dizzy or sleepy?

Official documentation does not list dizziness or sleepiness as common side effects. However, post-marketing reports have included instances of dizziness and difficulty sleeping (insomnia). Experiencing these effects often prompts consultation with a healthcare provider.


Q: How long does Gastrofrenal stay in the system?

The active ingredient in Gastrofrenal is generally known to be poorly absorbed from the gut into the bloodstream. Regulatory pharmacokinetic data suggests that the small amount that is absorbed is then rapidly cleared from the body by the liver and kidneys.


Q: Is Gastrofrenal an over-the-counter medicine?

No, Gastrofrenal is not an over-the-counter (OTC) medicine. It is classified as a Prescription only (Rx) product, and it requires a valid prescription for dispensing.


Q: Is there a generic version of Gastrofrenal available?

Yes. The active ingredient in Gastrofrenal is Cromolyn Sodium (also called Sodium Cromoglycate), which is the generic name. This compound is available in various forms and may be marketed as a generic product.


Q: Does Gastrofrenal cause weight gain?

Weight gain is not listed as a common or frequent side effect in the official safety information. However, the label notes that significant weight gain or swelling in the arms or legs is a condition typically reported to a healthcare provider.


Q: Can Gastrofrenal affect the results of my blood tests?

Post-marketing safety surveillance has included reports of the medicine affecting blood counts. These effects, though rare, have involved changes such as anemia (low red blood cell count), polycythemia, and neutropenia. Patients are generally advised to inform their healthcare professional that they are taking this medicine when having blood tests done.


Q: What is the official safety classification for Gastrofrenal?

Official product information, such as the New Zealand Data Sheet, classifies Gastrofrenal under the Pregnancy Category Category A. This classification is used when controlled studies in humans have not demonstrated a risk to the fetus.


Q: Do I need a special prescription for Gastrofrenal?

Yes, this medicine is available only via a prescription from a licensed doctor.


Q: Is Gastrofrenal the same kind of medicine as other common treatments for my condition?

Gastrofrenal is classified as a Mast Cell Stabilizer. This mechanism is distinct from common treatments like antacids or some anti-inflammatory drugs. It works by stabilizing immune cells to stop the release of allergy-causing chemicals, which differs from treatments that only neutralize acid or target inflammation directly.


Q: Does taking Gastrofrenal mean I need to change my diet?

Regulatory documents only impose a formal restriction that the dose must not be mixed with fruit juice, milk, or food. Consultation with a healthcare provider is generally recommended to discuss any potential restrictions on food, beverages, and activity.


Q: Are there any non-prescription medicines or supplements that interact with Gastrofrenal?

Official regulatory labels commonly state that patients should inform their healthcare provider about all prescription and non-prescription (OTC) medicines, vitamins, and herbal products currently being used. This is a general precaution for all concurrent medications.


Q: I'm feeling better, can I stop taking Gastrofrenal now?

Regulatory information advises against stopping the medicine suddenly without consulting a doctor. A rapid discontinuation may lead to a greater risk of the original symptoms returning or becoming worse.


Q: Why do some people report feeling nauseous after taking Gastrofrenal?

Nausea is listed in official documentation as a common side effect of the medicine. It is also often listed as a common symptom of the underlying conditions that the drug is used to treat (such as mastocytosis).


Q: Is Gastrofrenal known to interact with common pain relievers?

Regulatory-based sources indicate that the active ingredient in Gastrofrenal has no noted severe, serious, moderate, or minor interactions with other drugs, which includes common pain relievers.


Q: Is it safe to drink alcohol while taking Gastrofrenal?

Official prescribing information indicates that discussing the use of alcohol with a healthcare professional is necessary. While the medicine may not have a direct chemical interaction, a healthcare provider can advise based on an individual’s specific health profile and the effects of alcohol on their condition.


Q: Does Gastrofrenal interact with birth control pills?

Regulatory-based interaction data indicates that the active ingredient in Gastrofrenal has no noted severe, serious, moderate, or minor interactions with other drugs, including hormonal contraceptives like birth control pills.


Q: Is Gastrofrenal known to cause mood changes or depression?

While not a common effect, post-marketing reports have included psychiatric effects. These reports mention instances of depression, anxiety, and changes in behavior. These effects are typically monitored by a healthcare professional.


Q: Can Gastrofrenal be used by people with a history of allergies?

Gastrofrenal is classified as an anti-allergic agent, but it is strictly contraindicated (not allowed) if there is a known hypersensitivity or allergy to the medicine's active ingredient or any of its non-active components. It is also contraindicated if there is a history of anaphylactic shock to foods.


Q: Does Gastrofrenal interact with common cold and flu medications?

Regulatory-based sources indicate that the active ingredient in Gastrofrenal has no noted severe, serious, moderate, or minor interactions with other drugs, which would include common cold and flu preparations.

How should Gastrofrenal be stored and disposed of?

How to Store and Dispose of Gastrofrenal

Official regulatory documents prescribe specific conditions for storing Gastrofrenal (Sodium Cromoglycate). This medicine must be kept at Controlled Room Temperature, defined as 20 mathrmC to 25 mathrmC (68 mathrmF to 77 mathrmF), with protection from temperature extremes, including freezing.

Storage Protection and Stability

The product must be stored in its original, tightly closed container and kept protected from light. Any opened ampules of the oral solution should be used immediately to maintain product stability. As with all medications, Gastrofrenal must be stored out of the reach of children.

Disposal

Unused or expired medicine should be disposed of properly according to local requirements. Patients are instructed to consult their pharmacist or local waste disposal company for guidance on safely discarding this medication.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Gastrofrenal found in:

A-Z Index: